- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07830576
Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation
Construction of a Post-operative Multimodal Survival Prediction Model for Patients With Colorectal Liver Metastases: A Study Based on the Fusion of a Multicenter Cohort and High-dimensional Radiomics
The purpose of this study is to construct and validate a multimodal survival prediction model by integrating 3D radiomics features derived from preoperative magnetic resonance imaging (MRI) with systemic clinical baseline indicators for patients with colorectal liver metastases (CRLM) after surgery. By combining micro-level radiomics signatures reflecting tumor micro-heterogeneity with macro-level clinical parameters (such as liver function and tumor biomarkers), the study aims to accurately evaluate individual post-operative prognostic risks. This quantitative tool will provide reliable decision support for clinicians to customize post-operative follow-up and personalized adjuvant treatment strategies.
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is based on a strictly screened multicenter cohort of patients with colorectal liver metastases who underwent surgical intervention. First, high-throughput quantitative features are automatically extracted from the 3D regions of interest (ROIs) segmented based on pre-operative magnetic resonance imaging (MRI). Advanced machine learning dimensionality reduction algorithms are subsequently applied to eliminate redundant variables and select core imaging signatures that deeply reflect tumor micro-heterogeneity, microvascular proliferation, and invasive status. On this basis, these micro-level radiomics features are fused with macro-level clinical parameters, including liver function indexes and tumor load markers. Multivariable survival analysis models are performed to identify independent prognostic factors, which are further used to develop a visual and intuitive predictive nomogram tool. Finally, time-dependent evaluation metrics and an external validation cohort will be utilized to systematically test the dynamic predictive performance and cross-platform generalizability of the model. This multimodal dual-track data paradigm aims to achieve a non-invasive and efficient "digital optical biopsy" approach for prognostic evaluation.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: can zhang
- Phone Number: +8615755077865
- Email: 15755077865@163.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Recruiting
- The First Affiliated Hospital of University of Science and Technology of China
-
Contact:
- can zhang
- Phone Number: 15755077865
- Email: 15755077865@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population consists of adult patients diagnosed with colorectal liver metastases who underwent surgical resection across multiple participating clinical centers, featuring high-quality preoperative liver MRI scans and complete clinical follow-up histories.
Description
Inclusion Criteria:
Age >= 18 years old. Confirmed diagnosis of colorectal cancer with liver metastases (CRLM). Underwent surgical resection for colorectal liver metastases. Preoperative liver magnetic resonance imaging (MRI) was performed with high-quality images available for 3D radiomics feature extraction.
Complete baseline clinical, laboratory, and post-operative follow-up survival data.
Exclusion Criteria:
Patients who received local ablation only (such as radiofrequency ablation) without surgical resection.
Preoperative MRI images with severe artifacts or poor quality that prevent high-throughput radiomics analysis.
Concurrent history of other primary malignant neoplasms. Missing key clinical variables or lost to follow-up immediately after surgical intervention.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
CRLM Surgical Cohort
A multicenter cohort consisting of patients with colorectal liver metastases who underwent surgical resection. Preoperative magnetic resonance imaging (MRI) is utilized for 3D modeling and three-dimensional reconstruction of the liver and lesions, from which key spatial/morphological features and systemic clinical parameters are analyzed to predict post-operative recurrence-free survival. |
Observational and non-invasive assessment based on preoperative MRI-derived 3D modeling and three-dimensional lesion reconstruction, combined with clinical parameters, to build a survival prediction model. No experimental intervention is assigned. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recurrence-Free Survival (RFS)
Time Frame: Up to 5 years post-surgery
|
Recurrence-free survival (RFS) is defined as the time from the date of surgical resection to the date of first tumor recurrence (local, regional, or distant) or death from any cause, whichever occurs first. |
Up to 5 years post-surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jizhou Wang, MD, PhD, The First Affiliated Hospital of University of Science and Technology of China
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2026KY-249
- 2025AHGXZK10006 (Other Grant/Funding Number: Anhui Provincial Department of Education)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
To protect participant privacy and comply with institutional data governance policies, individual participant data from this retrospective study will not be publicly shared.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.